BROLUCIZUMAB FOR WET-AGED RELATED MACULAR DEGENERATION PATIENTS : TOO GOOD TO BE TRUE

Tania Purbonegoro (1) , M. Eko Prayogo (2) , A. Nurini Agni (3) , Tri Wahyu W. (4) , Supanji Supanji (5) , Firman S.W. (6) , M. Bayu Sasongko (7)
(1) Ophtalmology Resident Faculty of Medicine, Public Health, and Nursing, Gadjah Mada University , Indonesia
(2) Department of Ophthalmology, Faculty of Medicine, Public Health, and Nursing, Gadjah Mada University , Indonesia
(3) Department of Ophthalmology, Faculty of Medicine, Public Health, and Nursing, Gadjah Mada University , Indonesia
(4) Department of Ophthalmology, Faculty of Medicine, Public Health, and Nursing, Gadjah Mada University , Indonesia
(5) Department of Ophthalmology, Faculty of Medicine, Public Health, and Nursing, Gadjah Mada University , Indonesia
(6) Department of Ophthalmology, Faculty of Medicine, Public Health, and Nursing, Gadjah Mada University , Indonesia
(7) Department of Ophthalmology, Faculty of Medicine, Public Health, and Nursing, Gadjah Mada University , Indonesia

Abstract




Introduction & Objective: Brolucizumab is the newest anti-vascular endothelial growth factor (anti-VEGF) drug. It showed superior anatomic outcomes compared to other anti-VEGF and noniferiority best corrected visual acuity (BCVA) results for Wet-Aged Related Macular Degeneration (Wet-AMD) patients. In Yogyakarta, its been only used in few patients and we want to report the Effectiveness and safety of brolucizumab in Wet-AMD patients in Yogyakarta.


Method: In this retrospective study, all neovascular AMD (nAMD) Patients who underwent brolucizumab intravitreal injections between December 2021 and January 2023 at YAP Eye Hospital were studied. Patient’s demographic data, before and after intravitreal brolucizumab injections (central subfield thickness, intraocular pressure and BCVA) were assessed.


Result :This study included 6 eyes of 6 patients ( 3 women) with a mean age of 69.5 years old. The mean follow- up period was 27 ± 10.1 weeks after the first injection of brolucizumab. Three patients were naïve nAMD patient, never got any intravitreal injections and three anti-VEGF experienced nAMD patients with ranibizumab or aflibercept injections prior to brolucizumab. Mean BCVA at baseline (before brolucizumab injection) was 0.12 decimal (6/48) and was 0.29 decimal (6/20) at the last follow-up. Five out of six patients visual acuity were improved,one patient had constant bcva. Four out of six patient central subfield thickness were reduced, none of the patient intraocular pressure increased over 21 mmhg. None of the patient reported any signs of inflammation, vasculitis, or any other ocular or systemic adverse effects.


Conclusion :This limited data demonstrated that brolucizumab was safe and effective in stabilizing BCVA for both of nAMD patients who had undergone previous treatment with other anti-VEGFs agents and naive. Future larger multicenter collaborative studies are warranted.




Full text article

Generated from XML file

References

Brad H. Feldman, M.D., Vinay A. Shah M.D., Vinay A. Shah M.D., Leo A. Kim, MD, PhD, Koushik Tripathy, MD (AIIMS), FRCS (Glasgow), Jonathan C. Tsui, MD, Yasser M. Elshatory M. Age-Related Macular Degeneration. In: American Academy of Ophtalmology. 2022.

Tien Wong, MD P, Usha Chakravarthy, MD P, Ronald Klein, MD M, Paul Mitchell, MD P, Gergana Zlateva P, Ronald Buggage M, et al. The Natural History and Prognosis of Neovascular Age-Related Macular Degeneration. Ophthalmology. 2008;115(116–126).

Wolf AT, Harris A, Oddone F, Siesky B, Verticchio Vercellin A, Ciulla TA. Disease progression pathways of wet AMD: opportunities for new target discovery. Expert Opin Ther Targets. 2022;26(1):5–12.

Sharma A, Kumar N, Parachuri N, Sadda SR, Corradetti G, Heier J, et al. Brolucizumab—early real-world experience: BREW study. Eye [Internet]. 2021;35(4):1045–7. Available from: http://dx.doi.org/10.1038/s41433-020-1111-x

Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-erfurth U, Brown DM, et al. HAWK and HARRIER?: Phase 3 , Multicenter , Randomized , Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology [Internet]. 2020;127(1):72–84. Available from: https://doi.org/10.1016/j.ophtha.2019.04.017

Thomas CJ, Mirza RG, Gill MK, Frcs C. Age-Related Macular Degeneration. Med Clin NA [Internet]. 2021;105(3):473–91. Available from: https://doi.org/10.1016/j.mcna.2021.01.003

Schmidt-Erfurth U, Chong V, Loewenstein A et al. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists. Br J Ophthalmol. 2014;98:1144–67.

Boulanger-Scemama E, Querques G, About F et al. Ranibizumab for exudative age-related macular degeneration: a five year study of adherence to follow-up in a real-life setting. J Fr Ophtalmol. 2015;38:620–7.

Ferrante N, Ritrovato D, Bitonti R, Furneri G. Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy. BMC Health Serv Res [Internet]. 2022;22(1):1–11. Available from: https://doi.org/10.1186/s12913-022-07972-w

Authors

Tania Purbonegoro
tania.purbonegoro@mail.ugm.ac.id (Primary Contact)
M. Eko Prayogo
A. Nurini Agni
Tri Wahyu W.
Supanji Supanji
Firman S.W.
M. Bayu Sasongko
Purbonegoro, T., Prayogo, M. E. ., Agni, A. N. ., W., T. W. ., Supanji, S., S.W., F. ., & Sasongko, M. B. (2024). BROLUCIZUMAB FOR WET-AGED RELATED MACULAR DEGENERATION PATIENTS : TOO GOOD TO BE TRUE . Ophthalmologica Indonesiana, 49(S1), 98-102. https://doi.org/10.35749/99z4g547

Article Details

How to Cite

Purbonegoro, T., Prayogo, M. E. ., Agni, A. N. ., W., T. W. ., Supanji, S., S.W., F. ., & Sasongko, M. B. (2024). BROLUCIZUMAB FOR WET-AGED RELATED MACULAR DEGENERATION PATIENTS : TOO GOOD TO BE TRUE . Ophthalmologica Indonesiana, 49(S1), 98-102. https://doi.org/10.35749/99z4g547

Brolucizumab for Wet Aged-Related Macular Degeneration Patients : too Good to be True

Oral Presentation - Observational Study - Resident

Tania Purbonegoro, M. Eko Prayogo, A. Nurini Agni, Tri Wahyu W., Supanji, Firman S. W., M.B...
Abstract View : 28

THE OUTCOME OF INTRAVITREAL BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATMENT

Poster Presentation - Case Report - Resident

Gabriella Graziani, Grimaldi Ihsan, Made Indra Widyanatha, Rova Virgana, Arief S. Kartasasmita,...
Abstract View : 16